User login
Do inhaled beta-agonists control cough in URIs or acute bronchitis?
Patients who receive inhaled beta-agonists for cough due to acute upper respiratory infections (URI) are just as likely to report a productive cough at 7 days compared with patients treated with placebo (strength of recommendation [SOR]: A, based on a systematic review).
One trial, however, showed a reduction in overall cough at 7 days (number needed to treat [NNT]=3, SOR: B, a small randomized controlled trial), and another trial found a reduction in overall symptom score in smokers and those with wheezing on initial exam (SOR: B, based on a small randomized controlled trial).
Evidence summary
No studies of inhaled beta-agonists have been conducted with patients who have an explicit diagnosis of acute cough due to URI. While some clinicians feel a distinction between URI and acute bronchitis should be made, there is significant overlap between these diagnoses in clinical practice, as well as in the available studies.
A systematic review looking at beta-agonists for acute bronchitis included the clinical diagnoses of both acute bronchitis and acute cough because a standard definition of bronchitis is lacking.1 Only two trials in this review examined inhaled beta-agonists. When results from these trials were combined for the outcome of productive cough at 7 days, inhaled beta-agonists showed no benefit. However, the authors note that details of the individual trials may help to clarify the effect of inhaled beta-agonists.
One trial, a randomized controlled trial of adult patients with acute bronchitis in 2 community-based family practices, compared 23 patients receiving albuterolin a multidose inhaler (MDI) with 23 patients receiving placebo inhaler.2 Patients were also randomized to receive erythromycin or placebo tablets. Patients with pneumonia or a history of asthma or chronic obstructive pulmonary disease (COPD) were excluded. At 7 days, 61% of patients in the albuterol group reported cough compared with 91% in the control group (P=.02, NNT=3). No statistically significant difference was seen in productive cough or night cough. Smokers responded to inhaled albuterol similarly to nonsmokers. Erythromycin had no effect on cough and side effects were similar among all groups.
The other trial was a randomized controlled trial of 80 adults with cough due to acute respiratory infection; it compared fenoterol aerosol 4 times daily with placebo.3 Inhaled fenoterol is not available in the US but is similar to albuterol. This study showed no difference in cough at 7 days (relative risk [RR]=0.83; 95% confidence interval [CI], 0.52–1.30). In a subgroup analysis, however, smokers and those wheezing on initial exam had lower overall symptom scores when treated with fenoterol.
Recommendations from others
We were unable to find any guidelines on the use of albuterol via MDI for cough from bronchitis or URIs.
Inhaled beta-agonists may aid symptoms; other outcomes may not be improved
Even without a history of lung disease, patients presenting with cough due to acute respiratory illness and with evidence of airflow obstruction (wheezing) appear to receive symptom relief from inhaled beta-agonists. Smokers may be another subgroup who benefit from treatment. However, important patient-oriented outcomes (such as reduced need for over-the-counter medicines, general well being, and return to work) do not improve. If using inhaled albuterol to treat acute cough in practice, one must also consider the financial costs and adverse effects associated with treatment.
1. Smucny J, Flynn C, Becker L, Glazier R. Beta2-agonists for acute bronchitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
2. Hueston WJ. Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract 1994;39:437-440.
3. Melbye H, Aasebo U, Straume B. Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo controlled double-blind study. Fam Pract 1991;8:216-222.
Patients who receive inhaled beta-agonists for cough due to acute upper respiratory infections (URI) are just as likely to report a productive cough at 7 days compared with patients treated with placebo (strength of recommendation [SOR]: A, based on a systematic review).
One trial, however, showed a reduction in overall cough at 7 days (number needed to treat [NNT]=3, SOR: B, a small randomized controlled trial), and another trial found a reduction in overall symptom score in smokers and those with wheezing on initial exam (SOR: B, based on a small randomized controlled trial).
Evidence summary
No studies of inhaled beta-agonists have been conducted with patients who have an explicit diagnosis of acute cough due to URI. While some clinicians feel a distinction between URI and acute bronchitis should be made, there is significant overlap between these diagnoses in clinical practice, as well as in the available studies.
A systematic review looking at beta-agonists for acute bronchitis included the clinical diagnoses of both acute bronchitis and acute cough because a standard definition of bronchitis is lacking.1 Only two trials in this review examined inhaled beta-agonists. When results from these trials were combined for the outcome of productive cough at 7 days, inhaled beta-agonists showed no benefit. However, the authors note that details of the individual trials may help to clarify the effect of inhaled beta-agonists.
One trial, a randomized controlled trial of adult patients with acute bronchitis in 2 community-based family practices, compared 23 patients receiving albuterolin a multidose inhaler (MDI) with 23 patients receiving placebo inhaler.2 Patients were also randomized to receive erythromycin or placebo tablets. Patients with pneumonia or a history of asthma or chronic obstructive pulmonary disease (COPD) were excluded. At 7 days, 61% of patients in the albuterol group reported cough compared with 91% in the control group (P=.02, NNT=3). No statistically significant difference was seen in productive cough or night cough. Smokers responded to inhaled albuterol similarly to nonsmokers. Erythromycin had no effect on cough and side effects were similar among all groups.
The other trial was a randomized controlled trial of 80 adults with cough due to acute respiratory infection; it compared fenoterol aerosol 4 times daily with placebo.3 Inhaled fenoterol is not available in the US but is similar to albuterol. This study showed no difference in cough at 7 days (relative risk [RR]=0.83; 95% confidence interval [CI], 0.52–1.30). In a subgroup analysis, however, smokers and those wheezing on initial exam had lower overall symptom scores when treated with fenoterol.
Recommendations from others
We were unable to find any guidelines on the use of albuterol via MDI for cough from bronchitis or URIs.
Inhaled beta-agonists may aid symptoms; other outcomes may not be improved
Even without a history of lung disease, patients presenting with cough due to acute respiratory illness and with evidence of airflow obstruction (wheezing) appear to receive symptom relief from inhaled beta-agonists. Smokers may be another subgroup who benefit from treatment. However, important patient-oriented outcomes (such as reduced need for over-the-counter medicines, general well being, and return to work) do not improve. If using inhaled albuterol to treat acute cough in practice, one must also consider the financial costs and adverse effects associated with treatment.
Patients who receive inhaled beta-agonists for cough due to acute upper respiratory infections (URI) are just as likely to report a productive cough at 7 days compared with patients treated with placebo (strength of recommendation [SOR]: A, based on a systematic review).
One trial, however, showed a reduction in overall cough at 7 days (number needed to treat [NNT]=3, SOR: B, a small randomized controlled trial), and another trial found a reduction in overall symptom score in smokers and those with wheezing on initial exam (SOR: B, based on a small randomized controlled trial).
Evidence summary
No studies of inhaled beta-agonists have been conducted with patients who have an explicit diagnosis of acute cough due to URI. While some clinicians feel a distinction between URI and acute bronchitis should be made, there is significant overlap between these diagnoses in clinical practice, as well as in the available studies.
A systematic review looking at beta-agonists for acute bronchitis included the clinical diagnoses of both acute bronchitis and acute cough because a standard definition of bronchitis is lacking.1 Only two trials in this review examined inhaled beta-agonists. When results from these trials were combined for the outcome of productive cough at 7 days, inhaled beta-agonists showed no benefit. However, the authors note that details of the individual trials may help to clarify the effect of inhaled beta-agonists.
One trial, a randomized controlled trial of adult patients with acute bronchitis in 2 community-based family practices, compared 23 patients receiving albuterolin a multidose inhaler (MDI) with 23 patients receiving placebo inhaler.2 Patients were also randomized to receive erythromycin or placebo tablets. Patients with pneumonia or a history of asthma or chronic obstructive pulmonary disease (COPD) were excluded. At 7 days, 61% of patients in the albuterol group reported cough compared with 91% in the control group (P=.02, NNT=3). No statistically significant difference was seen in productive cough or night cough. Smokers responded to inhaled albuterol similarly to nonsmokers. Erythromycin had no effect on cough and side effects were similar among all groups.
The other trial was a randomized controlled trial of 80 adults with cough due to acute respiratory infection; it compared fenoterol aerosol 4 times daily with placebo.3 Inhaled fenoterol is not available in the US but is similar to albuterol. This study showed no difference in cough at 7 days (relative risk [RR]=0.83; 95% confidence interval [CI], 0.52–1.30). In a subgroup analysis, however, smokers and those wheezing on initial exam had lower overall symptom scores when treated with fenoterol.
Recommendations from others
We were unable to find any guidelines on the use of albuterol via MDI for cough from bronchitis or URIs.
Inhaled beta-agonists may aid symptoms; other outcomes may not be improved
Even without a history of lung disease, patients presenting with cough due to acute respiratory illness and with evidence of airflow obstruction (wheezing) appear to receive symptom relief from inhaled beta-agonists. Smokers may be another subgroup who benefit from treatment. However, important patient-oriented outcomes (such as reduced need for over-the-counter medicines, general well being, and return to work) do not improve. If using inhaled albuterol to treat acute cough in practice, one must also consider the financial costs and adverse effects associated with treatment.
1. Smucny J, Flynn C, Becker L, Glazier R. Beta2-agonists for acute bronchitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
2. Hueston WJ. Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract 1994;39:437-440.
3. Melbye H, Aasebo U, Straume B. Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo controlled double-blind study. Fam Pract 1991;8:216-222.
1. Smucny J, Flynn C, Becker L, Glazier R. Beta2-agonists for acute bronchitis (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
2. Hueston WJ. Albuterol delivered by metered-dose inhaler to treat acute bronchitis. J Fam Pract 1994;39:437-440.
3. Melbye H, Aasebo U, Straume B. Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo controlled double-blind study. Fam Pract 1991;8:216-222.
Evidence-based answers from the Family Physicians Inquiries Network